Key points are not available for this paper at this time.
Influenza exerts a considerable burden on adults aged ≥ 65 years and healthcare systems, with high incidence of hospitalization and mortality. Substantial influenza-associated clinical burden persists despite increasing vaccination coverage among adults aged ≥ 65 years across regions included in this review, which suggests limited effectiveness of currently available seasonal influenza vaccines. To reduce influenza-associated clinical burden, influenza vaccine effectiveness must be improved. Next generation vaccine production using mRNA technology has demonstrated high effectiveness against another respiratory virus-SARS-CoV-2-and may overcome the practical limitations associated with traditional influenza vaccine production.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jakob Langer
Verna Welch
Mary M. Moran
Advances in Therapy
Pfizer (United States)
Adelphi Group (United Kingdom)
Building similarity graph...
Analyzing shared references across papers
Loading...
Langer et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d75b1fef4aa71f97f30de0 — DOI: https://doi.org/10.1007/s12325-023-02432-1